-
1.发明申请Single nucleotide polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy 审中-公开单核苷酸多态性敏感地预测不良药物反应（adr）和药物功效公开(公告)号：US20070128597A1
公开(公告)日：2007-06-07
申请号：US10525278
申请日：2003-08-18
申请人： Stephan Schwers , Harald Kallabis , Udo Stropp
发明人： Stephan Schwers , Harald Kallabis , Udo Stropp
IPC分类号： C12Q1/68 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/6893 , G01N2800/32 , G01N2800/52
摘要： Single Nucleotide Polymorphisms sensitively predicting Advserse Drug Reactions (ADR) and Drug Efficacy Abs tract. The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-168 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译： 单核苷酸多态性灵敏预测Advancese药物反应（ADR）和药物功效性Abs。 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID 1-168，其具有如包含在功能性周围的序列部分中所示的等位基因变异，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。
-
2.发明申请Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy 审中-公开遗传多态性作为药物不良反应（adr）和药物功效的预测诊断公开(公告)号：US20060204962A1
公开(公告)日：2006-09-14
申请号：US10544049
申请日：2004-01-31
申请人： Udo Stropp , Stephan Schwers , Harald Kallabis , Gerd Schmitz
发明人： Udo Stropp , Stephan Schwers , Harald Kallabis , Gerd Schmitz
CPC分类号： C07K14/4702 , A61K38/00 , C07K14/7156 , C07K14/8132 , C12Q1/6876 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。
-
公开(公告)号：US20090208945A1
公开(公告)日：2009-08-20
申请号：US12097961
申请日：2006-12-19
申请人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
发明人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/42 , C12Q1/50 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G01N33/92
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。
-
4.发明申请Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy 审中-公开单核苷酸多态性灵敏预测不良药物反应（ADR）和药物疗效公开(公告)号：US20090138204A1
公开(公告)日：2009-05-28
申请号：US12255695
申请日：2008-10-22
申请人： Stephan Schwers , Harald Kallabis , Udo Stropp
发明人： Stephan Schwers , Harald Kallabis , Udo Stropp
IPC分类号： G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/6893 , G01N2800/32 , G01N2800/52
摘要： Provided are diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Also provided are polymorphic sequences and other genes and isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response.
摘要翻译： 提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者是否在他汀类药物治疗后患有不良药物反应的风险或人类受试者是高反应者还是低反应者 或他汀类药物的代谢不良。 诊断方法和试剂盒包括确定人类受试者是否处于心血管疾病风险的抗体。 还提供了多态性序列和其他基因和编码表型相关（PA）基因多肽的分离的多核苷酸，其可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法。
-
5.发明申请Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy 审中-公开遗传多态性敏感地预测不良药物反应（adr）和药物功效公开(公告)号：US20060240421A1
公开(公告)日：2006-10-26
申请号：US10524302
申请日：2003-07-28
IPC分类号： C12Q1/68 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID 1-21具有等位基因变异，如包含在功能性周围的序列部分中所示，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。
-
公开(公告)号：US08355874B2
公开(公告)日：2013-01-15
申请号：US12158744
申请日：2006-12-11
申请人： Andreas Schuppert , Rolf Burghaus , Christian Von Törne , Stephan Schwers , Udo Stropp , Harald Kallabis
发明人： Andreas Schuppert , Rolf Burghaus , Christian Von Törne , Stephan Schwers , Udo Stropp , Harald Kallabis
IPC分类号： G01N33/48
摘要： The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).
摘要翻译： 本发明涉及一种基于临床研究中获得的数据，用于预测治疗结果预后的生物标志物的方法，通过治疗将其保持不变的数据被细分为诊断和基因组参数，并且所述标记由参数组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目，并且因此指定从一开始的系统的最大复杂度，并且通过临时参数（= z参数）的顺序组合执行定义参数的搜索， 和/或基因组参数（= x参数）。
-
公开(公告)号：US20100190169A1
公开(公告)日：2010-07-29
申请号：US12640738
申请日：2009-12-17
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/00 , A61K48/00 , C12N9/14 , C12Q2600/156 , C12Y306/03009
摘要： The present invention relates to an isolated polynucleotide encoding a Na+/K+ ATPase polypeptide useful in methods to identify therapeutic agents useful for treating cardiovascular diseases, the polynucleotide is selected from the group consisting of:SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation G in position 240 contained in a functional surrounding like full length cDNA for Na+/K+ ATPase and with or without the Na+/K+ ATPase promotor sequence; and SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation A in position 240 contained in a functional surrounding like full length cDNA for Na+/K+ ATPase and with or without the Na+/K+ ATPase promotor sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.
摘要翻译： 本发明涉及编码用于鉴定治疗心血管疾病的治疗剂的方法中的Na + / K + ATP酶多肽的分离多核苷酸，所述多核苷酸选自：SEQ ID 4和SEQ ID 5（baySNP-1765） 位置240中的等位变异G包含在功能性周围，如Na + / K + ATP酶的全长cDNA，以及Na + / K + ATPase启动子序列中是否具有Na + / K + ATP酶启动子序列。 和SEQ ID 4和SEQ ID 5（baySNP-1765），其位置240中的等位基因变异A包含在功能性周围，如Na + / K + ATP酶的全长cDNA，以及Na + / K + ATPase启动子序列中或不含Na + / K + ATP酶启动子序列。 本发明还提供诊断方法和试剂盒，包括确定人类受试者是否处于心血管疾病风险的抗体。 本发明提供了更多的多态序列和其他基因。
-
8.发明申请Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy 审中-公开单核苷酸多态性预测不良药物反应和药物疗效公开(公告)号：US20050123919A1
公开(公告)日：2005-06-09
申请号：US10505936
申请日：2003-02-14
申请人： Udo Stropp , Stephan Schwers , Harald Kallabis
发明人： Udo Stropp , Stephan Schwers , Harald Kallabis
IPC分类号： A61P9/00 , C12N1/19 , C12N1/21 , C12N15/12 , C12N15/63 , C12Q1/68 , C07H21/04 , C12N9/22 , G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-80 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID1-80具有等位基因变异，如包含在功能性周围的序列部分中所示，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。
-
9.发明申请Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy 审中-公开遗传多态性作为不良药物反应（ADR）和药物功效的预测诊断公开(公告)号：US20090208967A1
公开(公告)日：2009-08-20
申请号：US12424803
申请日：2009-04-16
申请人： Udo Stropp , Stephan Schwers , Harald Kallabis , Gerd Schmitz
发明人： Udo Stropp , Stephan Schwers , Harald Kallabis , Gerd Schmitz
IPC分类号： C12Q1/68
CPC分类号： C07K14/4702 , A61K38/00 , C07K14/7156 , C07K14/8132 , C12Q1/6876 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。
-
公开(公告)号：US20090093689A1
公开(公告)日：2009-04-09
申请号：US12158744
申请日：2006-12-11
申请人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
发明人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
摘要： The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).
摘要翻译： 本发明涉及一种基于临床研究中获得的数据，用于预测治疗结果的预后的生物标志物的方法，通过治疗将其保持不变的数据被细分为诊断和基因组参数，并且所述标记由参数的组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目，并且因此指定从一开始的系统的最大复杂度，并且通过临时参数（= z参数）的顺序组合执行定义参数的搜索， 和/或基因组参数（= x参数）。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.027 秒)
